A detailed history of Bleakley Financial Group, LLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Bleakley Financial Group, LLC holds 15,943 shares of IBRX stock, worth $48,466. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,943
Previous 15,806 0.87%
Holding current value
$48,466
Previous $99.9 Million 40.63%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$3.32 - $6.7 $454 - $917
137 Added 0.87%
15,943 $59.3 Million
Q2 2024

Aug 12, 2024

BUY
$4.82 - $9.15 $24,018 - $45,594
4,983 Added 46.04%
15,806 $99.9 Million
Q1 2024

May 08, 2024

BUY
$3.23 - $6.17 $34,958 - $66,777
10,823 New
10,823 $58.1 Million

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.22B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Bleakley Financial Group, LLC Portfolio

Follow Bleakley Financial Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bleakley Financial Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bleakley Financial Group, LLC with notifications on news.